181065-46-3

Basic information

• Product Name: p-NH2-Bn-DOTA(B-200)
• Synonyms: p-NH2-Bn-DOTA(B-200);p-NH2-Bn-DOTA;1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 2-[(4-aminophenyl)methyl]-,(2S)-
• CAS NO: 181065-46-3
• Molecular Formula: C₂₃H₃₅N₅O₈
• Molecular Weight: 509.5527
• Mol File: 181065-46-3.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: p-NH2-Bn-DOTA(B-200)(CAS DataBase Reference)
• NIST Chemistry Reference: p-NH2-Bn-DOTA(B-200)(181065-46-3)
• EPA Substance Registry System: p-NH2-Bn-DOTA(B-200)(181065-46-3)

Safety Data

• Hazardous Substances Data: 181065-46-3(Hazardous Substances Data)

Usage

Uses

p-NH2-Bn-DOTA, is a Bifunctional chelator that can be used in the preparation of gadolinium complexes as MRI blood contrast agents.

Upstream product

• 1224513-61-4 2-(S)-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid tetrabenzyl ester 

Relevant articles and documents

Synthesis, in vitro progesterone receptors affinity of gadolinium containing mifepristone conjugates and estimation of binding sites in human breast cancer cells

Novel gadolinium-based mifepristone conjugates were synthesised using various synthetic routes. Moderate antiprogestagenic activity of the new conjugates was observed in human breast cancer cells (T47-D cells) using AP (alkaline phosphatase) assay. The amount of incorporated Gd determined by inductively coupled plasma mass spectroscopy (ICPMS) indicates the number of binding sites per cell. These conjugates might be important compounds to develop receptor-targeted MRI contrast agents as well as other anti-breast cancer therapeutics.